Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Total Current Liabilities (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Total Current Liabilities for 13 consecutive years, with $38.3 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 19.38% to $38.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $38.3 million through Dec 2025, up 19.38% year-over-year, with the annual reading at $38.3 million for FY2025, 19.38% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $38.3 million at Theravance Biopharma, up from $37.4 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $142.1 million in Q3 2022, with the low at $21.7 million in Q1 2024.
  • Average Total Current Liabilities over 5 years is $44.4 million, with a median of $32.4 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities crashed 82.15% in 2023, then surged 138.09% in 2025.
  • Over 5 years, Total Current Liabilities stood at $58.6 million in 2021, then tumbled by 50.99% to $28.7 million in 2022, then decreased by 13.75% to $24.8 million in 2023, then grew by 29.55% to $32.1 million in 2024, then rose by 19.38% to $38.3 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $38.3 million, $37.4 million, and $54.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.